HELP — CYBIN INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1833141 ·
Last close
$4.30
Market Cap
$214.54M
52W High
$6.26
52W Low
$3.76
ADV30
697,020
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -41,210,000 | -42,668,000 | 290,112,000 | 195,128,000 | 16,178,000 |
| Sep 2025 | 0 | — | -28,894,000 | -33,722,000 | 181,246,000 | 83,752,000 | 42,250,000 |
| Jun 2025 | 0 | — | -24,624,000 | -24,613,000 | 210,813,000 | 118,692,000 | 59,053,000 |
| Mar 2025 | 0 | — | -33,272,000 | -30,579,000 | 258,618,000 | 135,022,000 | 21,418,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-117,093,000
Investing CF
$-2,124,000
Financing CF
$219,389,000
CapEx
$-2,134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-342,540,000
Inventory
—
Receivables
$4,766,000
ST Investments
—
EBIT TTM
$-128,000,000
Pretax Income TTM
$-131,582,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 0 | -143,147,000 | -113,137,000 | 258,618,000 | 21,418,000 | — | -101,300,000 |
| Mar 2024 | 0 | -78,836,000 | -78,080,000 | 302,023,000 | 10,096,000 | — | -68,908,000 |
| Mar 2023 | 0 | -51,518,000 | -47,490,000 | 53,897,000 | 5,663,000 | — | -47,431,000 |
| Mar 2022 | 0 | -63,838,000 | -67,631,000 | 84,063,000 | 7,908,000 | — | -45,207,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | $214.33M | $12.64 | — |
| KPTI | Karyopharm Therapeutics Inc. | $215.30M | $9.50 | — |
| CNTN | Canton Strategic Holdings, Inc. | $215.70M | $3.09 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $212.61M | $1.58 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $211.81M | $0.20 | — |
News headlines (Yahoo Finance, 1h cache)
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
2026-06-11 11:30 · Yahoo
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
2026-06-01 11:30 · Yahoo
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 12:00 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-05-04 15:11 · Yahoo
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
2026-04-30 23:17 · Yahoo
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
2026-04-30 11:30 · Yahoo
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
2026-04-28 11:30 · Yahoo
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
2026-04-25 12:05 · Yahoo
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
2026-04-24 14:19 · Yahoo
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
2026-04-23 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.